KM Pharmaceutical Chairman Kang Il-mo Increases Stake by 1,200 Shares to 37.92% via Open Market Purchase

KM Pharmaceutical Chairman Kang Il-mo, a non-registered executive and major shareholder with over 10% stake, acquired an additional 1,200 common shares through open market purchases on July 6, 2026.
The purchase prices ranged from 1,700 KRW to 1,777 KRW per share, with an average of 1,727 KRW. As a result, his total holdings increased from 2,113,963 shares to 2,115,163 shares, raising his ownership ratio from 37.90% to 37.92%.
This small-scale share purchase does not involve new share issuance or dilution, and signals management's confidence in undervaluation and commitment to responsible management.
[AI Summary]Chairman Kang Il-mo's minor open market purchase increased his stake by only 0.02 percentage points, resulting in negligible financial impact. However, the insider buying demonstrates intent to support the stock price. No dilution risk is positive, but further value enhancement efforts are required.